Time Toxicity in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine Plus Cisplatin With or Without Durvalumab
N. Okano(Kyorin University), Mitesh J. Borad(Mayo Clinic Hospital), Oluseyi Abidoye(Mayo Clinic), Joachim L. Petit(Mayo Clinic Hospital), Binbin Zheng-Lin(WinnMed), Cody Eslinger(WinnMed), Pedro Luiz Serrano Usón(Hospital Israelita Albert Einstein), Yumei Zhou(Institute of Physics), Mohamad Bassam Sonbol(WinnMed), Mariko Nishioka(Kyorin University), Shuichi Hironaka(Kyorin University), Celine Hoyek(Mayo Clinic Hospital), Umair Majeed(Jacksonville College), Maria Fernanda Teixeira(Hospital Israelita Albert Einstein), Taro Sato(Kyorin University), Isabella Sforzin(Hospital Israelita Albert Einstein), C. O'Donnell(Mayo Clinic in Florida), Tanios Bekaii-Saab(Mayo Clinic Hospital), Hani M. Babiker(WinnMed), Daniel Ahn(Mayo Clinic Hospital), Fumio Nagashima(Kyorin University), Nguyen H. Tran(Mayo Clinic in Arizona), Masato Hayashi(Kyorin University), Christina Wu(Mayo Clinic Hospital), Lorenza Rimassa(Humanitas University), Elizabeth A. Raupach(Translational Genomics Research Institute), Angelo Pirozzi(Humanitas University), Natalie Elliott(Mayo Clinic in Arizona)
Cited by 0
Related Papers
Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
|The Journal of Clinical Endocrinology & Metabolism|2015|328
Martensitic transformation and shape memory effect in ferromagnetic Heusler alloy Ni2FeGa
|Applied Physics Letters|2003|272
Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients
|Leukemia|2006|90
Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers
|JCO Precision Oncology|2019|86
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
|European Journal of Cancer|2024|47